AlphAIalphai — Financial news for AI agents
kalkine.caAUG 262 min read$CLBT

Cellebrite DI Ltd (CLBT) Faces Securities Law Investigation After Q2 ARR Miss, CEO Change, and 29% Stock Drop

Cellebrite DI Ltd. (CLBT) is under investigation by Kaplan Fox & Kilsheimer LLP after missing Q2 ARR guidance of $507.8M (vs. $510M-$513M) and cutting full-year guidance by $15M. The company also replaced its CEO, leading to a 29% stock drop. Investors may monitor the investigation's progress.

Original reporting
kalkine.ca
Published Aug 26, 2026, 4:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 1:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$CLBT
Bearish
high confidence
Mentioned
$CLBT
Relevance
8/10
alphai data visualization · based on kalkine.ca
Decision brief

The 30-second read

$CLBTBearishMed
01

Why it matters

The earnings miss and abrupt CEO change caused a 29% share decline and prompted a securities‑law investigation.

02

Market read

The news is a primary corporate disclosure with immediate price impact and potential regulatory fallout.

03

What to watch

Potential upside from a foreign‑entity permit issue resolution and any undisclosed contract pipeline.

Relevance 8/10Novelty 8/10Timing: same‑day post‑earnings reaction

Background

Cellebrite DI Ltd. provides digital intelligence solutions; its Q2 results were released on Aug 13, 2026.

Company-level read

Ticker impact

$CLBTBearishHigh confidence
Context

Q2 ARR missed guidance, full-year outlook cut, CEO replaced; stock fell 29% on the news.

Expected impact

Further downside pressure expected as investigation details emerge.

Evidence & confidence

The combination of a material revenue shortfall, guidance reduction, and immediate CEO turnover is a strong bearish catalyst, amplified by a pending legal probe.

Market effects

Sector

Digital forensics and data‑recovery vendors may see heightened scrutiny on revenue guidance.

Regional

North American tech stocks could face short‑term pressure as investors reassess risk.

Global

Limited to firms with similar SaaS ARR models; no broad macro effect.

Counterpoint

What could challenge this read

If the investigation stalls, the stock may rebound on short‑covering and the price could stabilize.

Key entities

  • Law Firm
    Kaplan Fox & Kilsheimer LLP

    Plaintiffs' securities litigation firm leading the investigation.

  • Executive
    Shiv Ramji

    New CEO appointed effective immediately.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min
AUG 14
$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

simplywall.st3 min